Reasonable valuation given stock price underperformance. Adjusted Ebitda was 18% above estimates led by improvement in gross margin and cost …



Source link
#Sun #Pharma #Top #Nifty #Gainer #Analysts #Remain #Bullish #Results

Leave a comment

Your email address will not be published. Required fields are marked *